Title | Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapy. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Schoellnast H, Deodhar A, Hsu M, Moskowitz C, Nehmeh SA, Thornton RH, Sofocleous CT, Alago W, Downey RJ, Azzoli CG, Rosenzweig KE, Solomon SB |
Journal | Acta Radiol |
Volume | 53 |
Issue | 8 |
Pagination | 893-9 |
Date Published | 2012 Oct 01 |
ISSN | 1600-0455 |
Keywords | Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Catheter Ablation, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Length of Stay, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Surgery, Computer-Assisted, Survival Rate, Tomography, X-Ray Computed, Treatment Outcome |
Abstract | BACKGROUND: Radiofrequency ablation (RFA) is a potential application as a salvage tool after failure of surgery, chemotherapy, or radiotherapy of non-small cell lung cancer (NSCLC). Although several studies have evaluated the use of RFA in primary NSCLC, there is little literature on its potential application as a salvage tool. PURPOSE: To evaluate CT-guided RFA employed as a salvage therapy for pulmonary recurrences of NSCLC after prior treatment with chemotherapy, radiation therapy, and/or surgery. MATERIAL AND METHODS: A retrospective computer database search yielded 33 patients with biopsy proven primary NSCLC who underwent CT-guided RFA of 39 recurrent tumors following surgery, chemotherapy, and/or radiotherapy. Follow-up imaging was performed with CT and PET-CT. The endpoints of interest were progression-free survival (PFS) and time to local progression (TTLP). PFS and TTLP were compared by lesion size (<3 cm, ≥3 cm). RESULTS: The median PFS was 8 months. For patients with a tumor size <3 cm median PFS was 11 months, whereas the median PFS of patients with a tumor size ≥3 cm was 5 months. The difference did not reach statistical significance (P = 0.09). The median TTLP of all tumors was 14 months. TTLP of ablated tumors <3 cm in size was 24 months, compared to 8 months for ablated tumors ≥3 cm in size. The difference did not reach statistical significance (P = 0.07). CONCLUSION: RFA of recurrent NSCLC may be a valuable salvage tool to achieve local tumor control, especially in tumors measuring <3 cm in size. |
DOI | 10.1258/ar.2012.110333 |
Alternate Journal | Acta Radiol |
PubMed ID | 22961644 |